uploads///Aphria Analysts NTM Recommendation and Target

March Analyst Ratings and Price Targets for Aphria

By

Mar. 27 2018, Updated 7:31 a.m. ET

Aphria

Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date), which was similar to companies (HMMJ) such as MedReleaf (MEDFF) and Supreme Cannabis (SPRWF). In March, the stock reached a peak of 14.76 Canadian dollars but closed at its lowest point in March at 13.42 Canadian dollars on March 22, 2018.

Article continues below advertisement

Analyst ratings

As of March 22, the consensus analyst mean rating on Aphria was 1.75, which remained unchanged from the previous month. As we can see in the above chart, three analysts continue to have a “strong buy” recommendation, while four analysts continue to have a “buy” recommendation on the stock for the next-12-month period.

Also, one analyst has maintained a “hold” recommendation and none of the analysts have a “sell” recommendation on the stock, which is similar to CannTrust (CNTTF).

Price target

Similar to how the analyst ratings on Aphria remained unchanged month-over-month in March, the consensus mean price target has also remained unchanged at 23.19 Canadian dollars and the median price target remained unchanged at 26 Canadian dollars.

Aphria closed at 13.4 Canadian dollars on March 22, which leaves a 72.8% upside on the stock when compared to the mean price target. Compared with the median price target, we see an upside of almost 94% on the stock.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.